英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
iterum查看　iterum　在百度字典中的解释百度英翻中〔查看〕
iterum查看　iterum　在Google字典中的解释Google英翻中〔查看〕
iterum查看　iterum　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Iterum Therapeutics plc (ITRM)
    Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens
  • Iterum Therapeutics Receives U. S. FDA Approval of ORLYNVAH™ (Oral . . .
    Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the U S Food and Drug
  • ORLYNVAH™ :: Iterum Therapeutics plc (ITRM)
    ORLYNVAH™ (pronounced Or-lin-va) is the first FDA-approved oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options For more information or inquiries relating to ORLYNVAH™, visit
  • Our Company :: Iterum Therapeutics plc (ITRM)
    Iterum Therapeutics plc: Headquartered in Dublin, Ireland, we are dedicated to developing significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world
  • Our Promise :: Iterum Therapeutics plc (ITRM)
    Iterum was founded with one over-arching goal: to develop an antibiotic that addresses the growing crisis of multi-drug-resistant pathogens and meets the specific needs of physicians, their patients and other important stakeholders
  • Investor Relations :: Iterum Therapeutics plc (ITRM)
    Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world
  • Iterum Therapeutics Announces Positive Topline Results from its Phase 3 . . .
    Iterum has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications For more information, please visit www iterumtx com
  • Iterum Therapeutics Reports First Quarter 2025 Financial Results
    Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics
  • Iterum Therapeutics Announces Completion of Enrollment in its REASSURE . . .
    Iterum is currently advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation Sulopenem also has an IV formulation
  • Iterum Therapeutics Regains Full Nasdaq Compliance
    Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the U S Food and Drug





中文字典-英文字典  2005-2009